DANBURY, Conn. and WESTLAKE VILLAGE, Calif. - MannKind (NASDAQ:MNKD) Corporation (NASDAQ:MNKD) has announced preliminary results from its INHALE-3 Phase 4 clinical trial, indicating that inhaled insulin could be more effective at controlling post-meal blood sugar spikes in diabetics than traditional subcutaneous injections.
The study found a 20% reduction in post-meal hyperglycemia and a 22% decrease in mean glucose excursions within the first two hours after eating when using inhaled insulin compared to rapid-acting insulin delivered through injections or pumps.
The trial involved 141 patients over the age of 18 with type 1 diabetes (T1D), who were randomized to continue their standard care or begin a regimen of inhaled insulin plus a daily basal injection. The inhaled insulin group took their dose immediately before a standardized meal, while the control group used their usual rapid-acting insulin 5-15 minutes prior to eating. Notably, the inhaled insulin group reached peak glucose levels 15 minutes sooner than those on standard care, despite the timing of administration.
Dr. Irl B. Hirsch, who presented the data at the 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence, highlighted the need for better mealtime glucose control in diabetes management. MannKind's Senior Vice President, Dr. Kevin Kaiserman, expressed optimism about the safety and efficacy of inhaled insulin when appropriately dosed.
The full results of the 17-week trial are scheduled to be presented at the American Diabetes Association’s 84th Scientific Sessions on June 22. This announcement is based on a press release statement from MannKind Corporation.
Afrezza, the inhaled insulin used in the study, is indicated to improve glycemic control in adults with diabetes mellitus. However, it is not recommended for the treatment of diabetic ketoacidosis or for patients with chronic lung diseases such as asthma or COPD.
MannKind focuses on the development and commercialization of therapeutic products for endocrine and orphan lung diseases, utilizing its proprietary dry-powder formulations and inhalation devices. The company's mission is to improve the quality of life for patients by providing more control over their health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.